Pfizer (CHIX:PFED) Debt-to-EBITDA

: -10.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pfizer's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €9,487 Mil. Pfizer's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €55,478 Mil. Pfizer's annualized EBITDA for the quarter that ended in Dec. 2023 was €-6,496 Mil. Pfizer's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -10.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pfizer's Debt-to-EBITDA or its related term are showing as below:

CHIX:PFEd' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.85 Med: 2.61 Max: 7.41
Current: 7.41

During the past 13 years, the highest Debt-to-EBITDA Ratio of Pfizer was 7.41. The lowest was 0.85. And the median was 2.61.

CHIX:PFEd's Debt-to-EBITDA is ranked worse than
89.35% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs CHIX:PFEd: 7.41

Pfizer Debt-to-EBITDA Historical Data

The historical data trend for Pfizer's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

2.73

2.89

1.20

0.85

7.41

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA																1.23	1.08	3.76	-14.49	-10.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pfizer Debt-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pfizer's Debt-to-EBITDA falls into.

Pfizer Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pfizer's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(9487.282	+	55477.583)	/	8763.769
	=	7.41

Pfizer's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(9487.282	+	55477.583)	/	-6496.028
	=	-10.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Pfizer (CHIX:PFEd) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Pfizer Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pfizer's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (CHIX:PFED) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (CHIX:PFEd) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

PFE:USA PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy 0Q1N:UK PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer (CHIX:PFED) Headlines

No Headlines